Idera Pharmaceuticals (NASDAQ:IDRA) was downgraded by Zacks to a “neutral” rating in a research report issued on Thursday, Analyst Ratings Network reports. They currently have a $6.10 price objective on the stock. Zacks‘s price objective would suggest a potential upside of 5.35% from the company’s current price. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) stock opened at $5.62 in last session, and closed at $5.78, while the day range of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) stock is $5.25 – $5.85. The stock showed a positive weekly performance of -0.17%.
XOMA Corp. (NASDAQ:XOMA) was downgraded by research analysts at TheStreet from a “hold” rating to a “sell” rating in a report released on Friday, AR Network reports. XOMA Corp (NASDAQ:XOMA) stock opened at $6.59 in last session, and closed at $6.33 by losing -3.36%. The 52 week range of $2.91 – $9.57. Company’s market capitalization is $50.92 million.
NewLink Genetics Corporation (NASDAQ:NLNK) options contracts experienced a new 3-month record for both call and put contracts where a total of 6,494 call and 6,177 put contracts were traded in the busy trading session. The contract spread yielded a 0.95 put/call ratio. NewLink Genetics Corp (NASDAQ:NLNK) stock decreased -16.20% and finished the last session at $31.60. The EPS of the stock remained -1.23. Company’s market capitalization is $812.18 million.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) on Mar. 5 announced the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened the session at $23.99, and closed the session at $22.68. The 52 week range of the Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock remained $6.86 – $24.12 and the day range was $21.60 – $24.00.